The long-awaited has finally arrived ok by the European Medicines Agency (Ema) to the vaccine developed by AstraZeneca and University of Oxford, together with the Italian Advent-Irbm of Pomezia.
At this point, the vaccines available, with Pfizer-BioNtech and Moderna, become three.
Hope: good news
The comment of Health Minister Roberto Speranza was not long in coming, calling it encouraging news
The European drug agency has given the green light to the Astrazeneca vaccine. This is encouraging news. The battle against the virus is still complex, but having another effective and safe vaccine available gives us more strength in the vaccination campaign.
– Roberto Speranza (@robersperanza) January 29, 2021
AstraZeneca vaccine also valid for over 55s
It seems also solved the problem of the lack of security that it worked for the over 55.
The EMA explains that based on the experiences already acquired and the “information” available so far, “scientific experts consider that the vaccine can also be used in older adults”.
On the variants still too early to answer. The director of the EMA explained that the company was asked for the data, as with other pharmaceutical companies. The positive opinion on the vaccine was unanimous.
When the recall
AstraZeneca serum is administered in two doses and the second dose will need to be injected between the fourth and twelfth week after the first.
Side effects
The most common side effects are pain and tenderness at the injection site, headache, tiredness, body aches, general feeling of being unwell, chills, fever, joint pain and nausea. But they get better within days of vaccination.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
